

Amcil Limited ABN 57 073 990 735 Level 21, 101 Collins St Melbourne VIC 3000 T 03 9650 9911 F 03 9650 9100 invest@amcil.com.au amcil.com.au

28 May 2025

The Manager ASX Market Announcements Australian Securities Exchange Exchange Centre Level 4 20 Bridge Street Sydney NSW 2000

Electronic Lodgement

#### AMCIL Limited Evening Shareholder Information Meeting – Presentation

Dear Sir / Madam

Please find attached the presentation to be given at the Evening Shareholder Meeting being held today.

Yours faithfully

Matthew Rowe Company Secretary

ASX Release authorised by the Company Secretary.



## **Shareholder Meeting**









ASX: AFI

ASX: DJW

ASX: MIR




#### Disclaimer

Australian Foundation Investment Company, Djerriwarrh Investments Limited, Mirrabooka Investments Limited and AMCIL Limited and their service provider Australian Investment Company Services Limited (AICS) (AFSL 303209), their related entities and each of their respective directors, officers and agents (together the Disclosers) have prepared the information contained in these materials in good faith. However, no warranty (express or implied) is made as to the accuracy, completeness or reliability of any statements, estimates or opinions or other information contained in these materials (any of which may change without notice) and to the maximum extent permitted by law, the Disclosers disclaim all liability and responsibility (including, without limitation, any liability arising from fault or negligence on the part of any or all of the Disclosers) for any direct or indirect loss or damage which may be suffered by any recipient through relying on anything contained in or omitted from these materials.

This information has been prepared and provided by AICS. To the extent that it includes any financial product advice, the advice is of a general nature only and does not take into account any individual's objectives, financial situation or particular needs. Before making an investment decision an individual should assess whether it meets their own needs and consult a financial advisor.




#### Long Term Asset Class Returns



Sources: ABS, REIA, Global Financial Data, AMP Capital



### Australian Equity Market Returns – A Long Term Perspective



### Where the market is currently trading against the long term











## Where the US market is currently trading against the long term



Djerriwarr

RRABOOKA Investments Limited

## **Market volatility – positioning for future opportunities**



#### Trump tariffs

- Trade negotiations are driving volatility in markets and share prices in the immediate term
- Current policy uncertainty significantly affects business decision making
- Consequential earnings downgrades seem likely, though hard to quantify currently
- Ultimate tariff levels likely higher than previous, weighing on economic growth and increasing inflation
- Uncertain environment persists what changes next?












Diversified Australian and New Zealand Equities – capital and fully franked dividend growth over the long term





Fully franked yield that is higher than that available from the ASX 200 Index utilising option strategies, long term capital growth

Grossed up

dividend yield

7.4%

\$940 million

MER

0.42%



Australian and New Zealand small/midcap sector, capital growth over the long term and fully franked dividends

Grossed up

dividend yield

6.0%

\$625 million

MER

0.56%



High conviction portfolio, strong capital growth over the long term and fully franked dividends



Managing four funds with different investment objectives adds significantly to the effectiveness of the investment process and idea generation

No external funds management business taking a management and/or performance fees

Total FUM of approximately \$12 billion

Dividend yields based on share price on 30 April 2025

Internally managed – no external funds management business charging separate portfolio fees

Diversified portfolios that are tax aware with lower portfolio turnover and with lower volatility of returns

Costs and tax paid have less of an impact on returns – our performance quoted after fees and tax paid

Sensitivity to income requirements of shareholders – and franking credit and profit reserves

Incentives strongly aligned with shareholder interests, benefit of scale flows to shareholders

Independent Board of Directors









# A Closer Look at our Investment Approach

#### Attributes of a high-quality company that we seek:

- Unique assets that are hard to replicate or have an Industry leadership position (or developing one)
- Sustainability of competitive advantage
- Not unduly burdened by external risk factors
- Conservative balance sheets (low debt)
- Consistency of earnings
- Run by effective, passionate management with ownership alignment

#### Why this matters:

- The presence of these factors drives a competitive advantage
- Which leads to high return on capital
- And allows for reinvestment opportunities to drive growth
- Which allows for market share capture and further enhancement of leadership position
- Which combines to deliver long term shareholder value creation

We seek to buy these companies when we identify long term value and reduce or exit when they no longer meet these characteristics.









#### Australian Foundation Investment Company



• Net asset per share growth plus dividends, including franking

 S&P/ASX 200 Accumulation Index, including franking

Per annum returns. Assumes the full benefit of franking credits. Only includes franking that has been paid out. Past performance is not indicative of future performance.



Earnings per share excluding one offs ••• Ordinary dividends per share


AFIC's franking reserve balance (in part enabled by the LIC structure) ensures we can pay a consistent dividend even through volatile times.



#### **Portfolio Performance – to 30 April 2025**


#### Attractive Total Returns Over the Long-term

#### AFIC NTA vs S&P ASX 200 Accumulation Index




#### \$10k in AFIC **→ \$167k**

\$10k in the Index  $\rightarrow$  \$138k





## Portfolio Set to Perform in Most Economic Settings



Portfolio at 30 April 2025, excludes cash.



## **Banking Sector - Valuations**

Commonwealth Bank Price Earnings Ratio - NTM **Dividend Yield - NTM** 28 9 26 8 24 22 7 20 6 18 16 Average 5 14 Average 14.7 4 12 10 3 May 99 Mayot MayOS MayOS May and May way way way way way way way and May 1 May 19 May2 Not Source FactSet



#### **CSL - EPS vs Share Price**



Note: ASX 200 is indexed to company's share price Source: Diogenes Research

- Specialist biotechnology company that develops and manufactures therapies to treat serious chronic disease.
- Market leadership position in plasma fractionation operating more efficiently than competitors.
- Consistent investment in Research & Development of new pipeline drugs for longterm earnings growth.
- Despite challenges around tariffs and Covid disruption CSL has consistently delivered earnings growth.




## **Recent Portfolio Activity\***



\*Calendar Year 2025



### Djerriwarrh: Enhanced Yield - 30 April 2025\*




\*Assumes an investor can take full advantage of the franking credits. Yield based on the interim dividend and final dividend paid – in total 15.25 cents per share.

Past performance is not indicative of future performance.




### **Djerriwarrh: Capital Growth - 30 April 2025\***



**Portfolio Per Annum Returns** 

#### **Portfolio Performance Since Strategy Reset**



\*Assumes an investor can take full advantage of the franking credits.

Past performance is not indicative of future performance.



## **Portfolio Update: Summary**

Constructing a diversified portfolio of **high-quality** companies across different sectors and with the appropriate balance of **Income and Growth** is the key for Djerriwarrh to deliver on its Investment Objectives in a variety of market conditions.

#### **Key Portfolio Statistics**

<b>\$908m</b>	45
Portfolio Value*	Stocks in the Portfolio
45%	1%
Call Option Exposure	Put Option Exposure
\$3.	32
Net Tangible Asset (NT	A) Backing Per Share

Source: Based on 30 April 2025 Portfolio.


\* Portfolio Value is based on the Investment Portfolio plus the Trading portfolio, not including the Options portfolio.

#### Top 20 Holdings





#### Mirrabooka Portfolio Performance – Per Annum Returns to 30 April 2025\*



\* Assumes an investor can take full advantage of the franking credits. Mirrabooka's portfolio return is also calculate after management fees, income tax and capital gains tax on realised sales of investments. It should be noted that Index returns for the market do not include management expenses or tax. Past performance is not indicative of future performance.



### Mirrabooka Rights Issue

- 1 for 7 Rights Issue Non Renounceable. Raising up to approximately \$85 million.
- Issue price of \$3.06\* approximately 5% discount to current share price.
- New shares entitled to dividend of 6.5 cents with results in July<sup>^</sup>. Paid in August.
- Shareholders can apply for more than their entitlement but may be subject to scale back.
- Entitlement Offer closes 2 June 2025.

\*Equal to the average of the weekly estimated pre-tax value of the net tangible asset backing per Mirrabooka share over the period from Friday, 4 April 2025 to Friday, 2 May 2025 (inclusive)

<sup>^</sup>The amount, and payment, of this final dividend remains subject to approval by the Mirrabooka Directors at the time of approval of the annual financial statements of Mirrabooka in July 2025



## **Rationale for raising additional capital**

- Market volatility we have seen greater opportunities arise in early 2025, positioning for more
- Replenishing capital since our first special dividend in 2013, \$81 mil paid out in cash dividends and Capital Gains Tax, net of capital raised through DRPs and SPPs
- Investment flexibility tax effective portfolio repositioning as selected stock weightings can be reduced without selling down holdings
- Mirrabooka shareholders have consistently expressed interest in supporting further capital raising
- Significant franking credit reserves to support dividend capacity on additional shares
- Scale absence of FUM linked fees means shareholders benefit from reduced MER



#### **Greater investment opportunities – stock purchases in 2025 YTD**

#### \$72 million of purchases across 40 stocks, largest below:





## Mirrabooka Top 20 Holdings – 30 April 2025

	Company	% of Portfolio	Ownership Period	Company	% of Portfolio	Ownership Period
1	macquarie TECHNOLOGY GROUP	5.2%	8 yrs	11* HUB <sup>24</sup>	2.3%	9.5 yrs
2*	TEMPLE <sup>ど</sup> WEBSTER	4.4%	5 yrs	12 Region	2.3%	1.5 years
3	ARB	4.0%	14.5 yrs	13 Breville	2.3%	7.5 yrs
4	<b>O</b> gentrack <sup>™</sup>	3.6%	3 yrs	14 💦 idp	2.2%	4 yrs
5	ALS	3.5%	19.5 yrs	15* netwealth	2.0%	7.5 yrs
6	ResMed	3.3%	13.5 yrs	16 🥢 JamesHardie	1.9%	6.5 yrs
7	evt	2.8%	14.5 yrs	17 <b>Objective</b>	1.8%	10 yrs
8	Equity Trustees	2.8%	19.5 yrs	18 UB GROUP	1.7%	19 yrs
9		2.6%	9.5 yrs	19 CLEANAWAY	1.6%	6 yrs
10	CAR Group	2.4%	8.5 yrs	20* ① REA Group	1.6%	5 yrs

\* Indicates that options were outstanding against part of the holding.


Note: ResMed, Breville Group, Vista Group, IDP Education, James Hardie and REA Group have been held previously by Mirrabooka.



### Mirrabooka's track record – since inception return

Mirrabooka 12.2%

\$10k invested at Mirrabooka inception in April 1999 – dividends reinvested and franking credits refunded




Mid/Smallcaps 8.4%



ASX200 9.7%


### **AMCIL Portfolio Performance – Per Annum Returns to 30 April 2025\***



\* Assumes an investor can take full advantage of the franking credits. AMCIL's portfolio return is also calculated after management fees, income tax and capital gains tax on realised sales of investments. It should be noted that Index returns for the market do not include management expenses or tax. Past performance is not indicative of future performance.



## **Recent Portfolio Activity\***



\*Calendar Year 2025



# AMCIL Top 20 Holdings (update)

Company	% of Portfolio	Ownership Period		Company	% of Portfolio	Ownership Period
CSĽ	8.0%	13 yrs	11*	ResMed	3.0%	5 yrs
MACQUARE	5.7%	7 yrs	12*	netwealth	2.6%	3 yrs
; Goodman	4.7%	5 yrs	13*	James Hardie	2.6%	13 yrs
* Wesfarmers	4.5%	6 yrs	14*	Equity Trustees	2.4%	7 yrs
BHP	4.3%	21 yrs	15	III I wisetech ' I ' global	2.4%	2 yrs
	4.3%	5 yrs	16*	estpac	2.2%	3 yrs
	4.0%	9 yrs	17*	🔆 nab	2.1%	2 yrs
Transurban	4.0%	15 yrs	18*	REA Group	2.0%	5 yrs
CAR Group	3.8%	7 yrs	19*	ALS ALS	2.0%	2 yrs
ARB	3.3%	14 yrs	20	<b>O</b> gentrack <sup>®</sup>	2.0%	2 yrs



#### Share price relative to Net Asset Backing – 30 April 2025

